Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Lyell Immunopharma (LYEL)

Annual Return

Over the past 3 years, LYEL has had an average annual return of -41.23%, underperforming the benchmark SPY, which returned +19.63% annual.

Over the past 5 years, LYEL has had an average annual return of -46.95%, underperforming the benchmark SPY, which returned +12.73% annual.

Since Jun 17, 2021, LYEL has had an average annual return of -47.15%, underperforming the benchmark SPY, which returned +13.47% annual.

202620252024202320222021
-57.41%+140.37%-67.01%-44.06%-55.18%-54.17%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-22.06%+0%-16.34%-1.68%-12.16%-18.91%-6.73%-57.41%
2025-7.92%+20.63%-24.23%-11.91%-7.83%+1.16%+33.59%-6.29%+46.65%+2.49%+44.02%+28.31%+140.37%
2024-5.74%+59.65%-23.66%-2.65%+27.63%-47.68%+11.07%-9.97%-4.78%-30.35%-1.58%-32.32%-67.01%
2023-5.74%-34.25%+9.74%-13.96%+57.15%-0.32%-9.13%-17.30%-38.52%+12.64%+4.49%+12.21%-44.06%
2022-26.62%+27.48%-30.25%+1.57%-19.30%+57.49%-14.56%+20.29%+9.40%-19.79%-28.38%-17.61%-55.18%
2021-3.85%-10.71%+8.90%-6.27%-5.82%-31.49%-18.94%-54.17%

Drawdown analysis of Lyell Immunopharma (LYEL)

The maximum drawdown for the LYEL was -97.83%, occurring on May 14, 2025. This drawdown has not yet recovered.

The current LYEL drawdown is -96.35%.

Since Jun 17, 2021 LYEL has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 2 times
  • 10% or more: 2 times
DepthStartTo BottomBottomTo RecoverEndTotal
-97.83%Sep 10, 2021922May 14, 2025OngoingOngoingOngoing
-20.11%Jul 16, 20218Jul 28, 202128Sep 7, 202136
-9.71%Jun 17, 202114Jul 8, 20216Jul 16, 202120
-1.12%Sep 8, 20211Sep 9, 20211Sep 10, 20212